SevenBridge Financial Group LLC Sells 37,323 Shares of Pfizer Inc. (NYSE:PFE)

SevenBridge Financial Group LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 22.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 131,644 shares of the biopharmaceutical company’s stock after selling 37,323 shares during the quarter. SevenBridge Financial Group LLC’s holdings in Pfizer were worth $3,361,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the 4th quarter valued at $28,000. Noble Wealth Management PBC bought a new position in Pfizer in the 4th quarter worth $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer in the 4th quarter worth $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PFE. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

NYSE PFE opened at $24.53 on Wednesday. The company has a market cap of $139.09 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.64 and a beta of 0.61. The business’s 50 day moving average price is $26.00 and its 200-day moving average price is $26.84. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.